by The Epidermolysis Bullosa Market is estimated to be valued at US$ 3813.38 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Epidermolysis bullosa (EB) is a group of rare inherited disorders that cause easy blistering of the skin and mucous membranes. The blisters can occur in response to minor injury, friction, or physical stress. Some subtypes of EB are also associated with blistering of the internal body linings, such as the gastrointestinal tract or lungs. There are three major types of EB: EB simplex, dystrophic EB, and junctional EB. EB simplex is further categorized into four subtypes based on clinical severity. EB simplex causes blisters in the superficial layers of the skin and oral mucous membranes. Dystrophic EB causes blisters in the dermis, the layer beneath the outer layer of skin, and can lead to scarring and contractures. Junctional EB is the most severe type and causes blisters in the lamina lucida, a thin layer of tissue just beneath the epidermis, and is often associated with woolly hair and nail abnormalities.
Market Dynamics:
The increasing R&D activities for developing treatments for EB is expected to drive the growth of the EB market over the forecast period. For instance, Amryt Pharma is developing LOJUXTA (Oleogel-S10) for the treatment of dystrophic and junctional EB. LOJUXTA is a topical film forming gel containing 10% w/w oleogel-S (anethole trithione stabilized in an anhydrous gel) in a lipophilic and emollient isododecane base. Moreover, Abeona Therapeutics is also developing EB-101, an autologous, gene-corrected cell therapy for patients with RDEB. EB-101 has received fast track designation from the U.S. FDA for the treatment of RDEB. Other companies such as Castle Creek Pharmaceuticals, RHEACELL GmbH, Holostem Terapie Avanzate are also developing cell and gene based therapeutics for EB which is further expected to propel the market growth. Additionally, increasing awareness about EB disease is also anticipated to aid the market growth over the forecast period.
Segment Analysis
The global Epidermolysis Bullosa market is dominated by the non-transient, dominant dystrophic EB sub-segment which accounts for around 50% share of the total market. Non-transient dystrophic EB refers to a group of inherited skin disorders characterized by fragile skin that blisters easily from minimal friction or trauma. It is dominating because it has the highest prevalence among all EB sub-types and has a lifespan severely decreased quality of life due to widespread blister formation and scarring across the body.
PEST Analysis
Political: Government focus on orphan drugs and investments to foster innovation in rare disease treatment is favoring market growth. Economic: Increasing GDP and healthcare spending in emerging economies is driving patients access to EB treatment. Social: Rising disease awareness and patient support groups are encouraging research. Technological: Advancements in gene therapy and regenerative medicine holds promise to provide permanent cure.
Key Takeaways
The Global Epidermolysis Bullosa Market Size is expected to witness high growth, exhibiting CAGR of 11% over the forecast period, due to increasing research funding and pipeline drugs. North America dominates the market currently due to higher adoption of advanced treatment options followed by Europe. Key players operating in the Epidermolysis Bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair.
The global Epidermolysis Bullosa market size was valued at US$ 3813.38 Mn in 2023. North America is expected to remain the fastest growing regional market over the forecast period owing to rising EB prevalence, strong healthcare infrastructure, and availability of advanced treatment options in the region. The United States accounts for the largest share in the North American as well as global EB market.
Key players operating in the Epidermolysis Bullosa market are focusing on developing novel gene therapies and stem cell therapies to overcome limitations of existing symptomatic treatments. Krystal Biotech and Castle Creek Pharmaceuticals are developing topical gene therapies while Abeona Therapeutics and RegeneRx are developing injectable gene therapies for EB. Amryt Pharma and StemRim/Shionogi are investigating allogeneic stem cell therapies which can potentially provide lifelong cure.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
